Clinical trial
The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With…
NCT00277550 · Novartis, Industry · Withdrawn
Key facts
| NCT number | NCT00277550 |
|---|---|
| Title | The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia |
| Official title | A Randomized, Double-blind, Placebo-controlled Evaluation of the Effects of Tegaserod (6 mg b.i.d) on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia |
| Lead sponsor | Novartis, Industry |
| Collaborators | Mayo Clinic |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Constipation and Dyspepsia |
| Intervention type | Drug |
| Interventions | Tegaserod and Placebo |
| Enrollment | 0 |
| First posted | Jan 16, 2006 |
| Last update posted | Mar 4, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: